Medically reviewed by Dr. C.H. Weaver M.D. Medical Editor 6/2021
Because sarcomas are uncommon it is important to find physicians who have experience with this disease. In the United States there are several locations that have physicians and teams dedicated to advancing the treatment of GIST and other sarcomas. Patients with sarcoma should at least consider getting a second opinion at one of these centers. Click here to learn more about second opinions.
Clinical trials are an important aspect of moving sarcoma treatments forward and patients should consider being evaluated and treated at a cancer center with expertise in Sarcomas. For example the following clinical trials are ongoing at the Seattle Cancer Care Alliance Sarcoma program
- A Phase 2 trial of an innovative T-cell therapy in participants with advanced synovial sarcoma or myxoid/round cell liposarcoma. This trial tests a modified T-cell that is directed at one of the most commonly expressed cancer-testis antigens, MAGE-A4. The study is among a growing number of trials that aim to use T-cells to infiltrate and destroy solid tumors.
- A Phase 3 study that compares efficacy of two targeted second-line therapies, Ripretinib and Sunitinib, in treating gastrointestinal stromal tumors (GIST) if patients have not responded well or tolerated the typical first-line treatment, Imatinib. The two drugs in the study can potentially block the KIT mutations that spur GIST growth.
- A pilot Phase 2 study of Oraxol in patients with cutaneous angiosarcoma. In 2018, the FDA gave Oraxol an orphan drug designation for angiosarcoma treatment, and this study’s interim results showed a reduction in tumor size in all evaluable patients.
For sarcoma referrals, contact:
- Phone: (206) 606-7376 - Email: email@example.com
University of Arizona
Univ of California Davis Sarcoma Program
Johns Hopkins (Baltimore, MD)
Dana Farber Cancer Institute (Boston, Massachusetts)
Ask the Experts About Circulating Tumor DNA in the Management of Cancer
Ask the Experts About Circulating Tumor DNA (ctDNA) in the Management of Cancer
Tisotumab Vedotin – Promising in Advanced Cervical Cancer
Novel precision cancer medicine promising for treatment of advanced ovarian cancer.
Checkpoint Inhibitor Immunotherapy for Treatment of Advanced Cervical Cancer
Checkpoint inhibitor immunotherapy prolongs survival and delays recurrence in advanced cervical cancer.
Washington D. C.
Washington Cancer Institute (Washington DC)